Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

Alpha-1-Proteinase Inhibitor Human · Zemaira

Plasma-derived product · Protein replacement · developed by CSL Behring LLC

Approved FDA, Jul 2003
1 Registered trials

What is Alpha-1-Proteinase Inhibitor Human?

Alpha-1-Proteinase Inhibitor (Human) is a purified human serum-derived alpha-1 proteinase inhibitor, also called alpha-1-antitrypsin, a serine protease inhibitor of the serpin superfamily. It is studied in pulmonary emphysema associated with alpha-1 proteinase inhibitor deficiency.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Zemaira, Alpha-1 MP
Drug type
Plasma-derived product
Mechanism
Protein replacement
Pathways
cytokine signaling (TNF-alpha, IL-1 beta, IL-6, IL-10 modulation), cAMP/protein kinase A activation, dendritic cell maturation and T cell regulation
Therapy area
Respiratory
Developer
CSL Behring LLC
In trials of
GRFS
FDA status
Approved as Zemaira (July 8, 2003), BLA125078
UNII
F43I396OIS

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT01983241 Phase 3 Pulmonary Emphysema in Alpha-1 PI Deficiency Completed GRFS

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Pulmonary Emphysema in Alpha-1 PI Deficiency

Sources

Updated Oct 11, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.